BillionToOne, Inc. (BLLN)
Health Care · molecular diagnostics · NASDAQ
BillionToOne is a molecular diagnostics company utilizing AI-driven technology to innovate non-invasive prenatal testing and oncology diagnostics.
What BillionToOne, Inc. does
BillionToOne, Inc. is a molecular diagnostics company that develops and commercializes advanced diagnostic tests for the prenatal and oncology markets. The company leverages proprietary technology and artificial intelligence to improve the sensitivity and accuracy of its diagnostic platforms, aiming to expand its presence within large healthcare systems.
Themes: molecular diagnostics, prenatal screening, oncology diagnostics, AI in healthcare, companion diagnostics
Fundamentals
- Price$104.67 as of 2026-10-21 close
- Market cap$4.8B market cap from Nasdaq, 2026-10-21
- P/En/a not reported by our data source
- Net margin+2.4% FY2025, SEC XBRL
- Gross margin+68.3% FY2025, SEC XBRL
- ROE+1.6% FY2025, SEC XBRL
- ROICn/a No figure: its cash offsets more than 80% of its debt and equity, so the ratio would divide by a small residual.
- Debt / equity0.17 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+100.0% FY2025, SEC XBRL
- Revenue CAGR (3y)+106.2% SEC XBRL
- Beta1.74 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How BLLN compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
BLLN is not currently in any published Top 10 list. Its scores are below.
Top 10 score
48.5 #771 of 1,265 scored · #101 of 145 in Health Care
Growth 99th (3-year revenue CAGR 106.2%, revenue growth year over year 100%) and financial health 60th (debt to equity 0.2, free cash flow margin 5.2%); weakest is capital return (18th, consecutive years of dividend increases 0 years).
Scores as of 21 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $109M | $77M | $6M | $8M | $0.15 | $9M† | $4M† |
| Q1 FY2026 2026-03-31 | $108M | $79M | $18M | $18M | $0.34 | $15M | $4M |
| Q4 FY2025 2025-12-31 | $96M† | $69M† | $10M† | $6M† | $0.11† | $11M† | $2M† |
| Q3 FY2025 2025-09-30 | $84M | $58M | $10M | $6M | $0.10 | $10M† | $2M† |
| Q2 FY2025 2025-06-30 | $67M | $43M | -$2M | -$246000 | -$0.02 | $1M† | $3M† |
| Q1 FY2025 2025-03-31 | $59M | $38M | -$2M | -$4M | -$0.39 | $3M | $2M |
| Q4 FY2024 2024-12-31 | $45M† | $26M† | -$12M† | -$11M† | -$1.13† | -$8M† | $2M† |
| Q3 FY2024 2024-09-30 | $38M | $20M | -$13M | -$15M | -$1.47 | — | — |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$549M
- Total debt$91M borrowings only; leases excluded
- Net debt-$458M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How BillionToOne, Inc. looks technically
BillionToOne, Inc. (BLLN) is trading 9.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average has held above its 200-day average for at least 31 trading days — a long-sustained "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 8 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 9.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +9.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $101.26 | $101.26 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $95.50 | $95.50 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 90.48. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average has held above its 200-day average for at least 31 trading days — a long-sustained "golden cross", a bullish long-term signal | at least 31 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 15.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 51.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($90.48 to $112.87) — its "stochastic" reading is 63 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 63.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
7
| Since a 20-day breakout | it made a new 20-day low about 8 trading days ago | 8 sessions |
|---|---|---|
| Since a 55-day breakout | it made a new 55-day high about 55 trading days ago | 55 sessions |
| All-time high | its highest closing price on record is $150.44 (set on 2026-08-05) | $150.44 |
| Given back of the 52-week move | not available for this company yet | n/a |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $61.96 (set on 2026-03-12) | $61.96 |
| Above the all-time low | it is 68.9% above its all-time low | +68.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 61st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $6.51 between its high and its low — about 6.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $6.51 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $85.89 and $124.07 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $85.89 – $104.98 – $124.07 |
| Typical daily range (% of price) | its price moves about 6.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.2% |
| Stretch from the 200-day average | it is trading 1.4 daily ranges above its 200-day average price (9.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.60× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a hammer | 9 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 9 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-21 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Open gap | it gapped 2.1% above the previous close 44 sessions ago and has not traded back through the level it left behind at 87.99 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.1% |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +6.68% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 0.8 percentage points (the stock gained 0.8% while the market lost 0.1%) | +0.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 24.3 percentage points (the stock lost 21.0% while the market gained 3.3%) | -24.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 7.8 percentage points (the stock gained 17.6% while the market gained 9.8%) | +7.8% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 20.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $99.23 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | +5.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $101.48 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | +3.1% |
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $90.48.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $128.41 and $151.86 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $90.48.
This reading has stood for 2 trading days, since 2026-10-20.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · Most volatile (6%+ typical daily range) · Trading inside the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$129.00 range $110.00 – $145.00; median $130.00
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BLLN
- Consensus EPS estimate$0.3 next reporting period, as of 2026-10-20
- Estimate change, 30 days$0.00 (0.0%) from $0.3, on 2026-09-16, 34-day window
- Readings revised upward10% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant competition in the molecular diagnostics industry, including potential legal proceedings from competitors.","Dependence on the successful adoption of new products and the ability to expand reimbursement coverage for existing tests.","Risk of failing to maintain effective internal controls over financial reporting or failing to remediate existing material weaknesses."]
What changed in the latest 10-Q
AI-assisted comparison of BLLN's 10-Q filed 2026-08-05 against the prior one filed 2026-05-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds: 'In August 2026, we announced the upcoming expansion of the Unity Fetal Risk Screen with the addition of a 130-gene panel, which is currently the largest single-gene NIPT panel available.'
- Newer filing adds: 'and in August 2026 we announced the launch of Northstar Origin TM .'
- Newer filing adds: 'Northstar Origin is an add-on tissue-of-origin feature for our Northstar Select test that can benefit patients with unknown or uncertain diagnoses.'
- Removed:
- Older filing contains a sentence continuing after 'Our total test volume...' that describes delivered and billable test volume of approximately 188,000 tests for the three months ended March 31, 2026, compared to 131,000 for the three months ended March 31, 2025; this sentence is not present in the newer filing's excerpt (which appears truncated).
- Reworded:
- Older filing states 'we have processed more than one million smNGS-based tests'; newer filing states 'we have processed more than one and a half million smNGS-based tests'.
- Older filing states 'we test approximately 1 in 11 babies during pregnancy in the United States'; newer filing states 'we test more than 1 in 10 babies during pregnancy in the United States'.
- Older filing states 'over 45% of them, or approximately 676,000 tests, were processed within the last 12 months ended March 31, 2026'; newer filing states 'over 42% of them, or approximately 726,000 tests, were processed within the last 12 months ended June 30, 2026'.
- Older filing references 'Northstar PGx, and in February 2026, we launched Northstar Select CH. Northstar PGx and Northstar CH are add-on applications...'; newer filing references 'Northstar Select CH TM , and in August 2026 we announced the launch of Northstar Origin TM . Northstar PGx and Northstar Select CH are add-on applications...'.
- Older filing states 'our total test volume...grew to approximately 189,000 tests for the three months ended March 31, 2026, compared to 137,000 for the three months ended March 31, 2025'; newer filing states 'our total test volume...grew to approximately 197,000 tests for the three months ended June 30, 2026, compared to 148,000 for the three months ended June 30, 2025'.
- Notes:
- The newer filing excerpt is truncated at 'which represents th', so content beyond that point cannot be compared.
- The older filing excerpt is truncated at 'operating performance and', so content beyond that point cannot be compared.
Risk Factors
- Added:
- Newer filing (2026-08-05) reports unregistered issuance of 113,116 shares of Class A common stock to Western Alliance Bank on May 6, 2026 upon net exercise of warrants (80,357 at $2.80 and 41,209 at $10.92, with 8,450 shares withheld).
- Newer filing (2026-08-05) reports issuance of 10,000 shares of Class A common stock to Oguzhan Atay on June 8, 2026 upon conversion of equivalent Class B shares.
- Newer filing (2026-08-05) states belief that the above securities sales were exempt from registration under Section 3(a)(9) of the Securities Act.
- Newer filing (2026-08-05) reports Rule 10b5-1 trading arrangement for John ten Bosch entered June 2, 2026, covering sale of up to 12,750 shares between September 9, 2026 and December 4, 2026.
- Newer filing (2026-08-05) reports Rule 10b5-1 trading arrangement for Oguzhan Atay entered June 5, 2026, covering exercise of up to 100,000 stock options and sale of underlying shares between September 14, 2026 and November 27, 2026.
- Newer filing (2026-08-05) reports Rule 10b5-1 trading arrangement for David Tsao entered June 5, 2026, covering exercise of up to 70,000 stock options and sale of underlying shares between September 9, 2026 and December 4, 2026.
- Newer filing (2026-08-05) reports Rule 10b5-1 trading arrangement for Thomas Lynch entered June 8, 2026, covering exercise of up to 38,226 stock options and sale of underlying shares between September 8, 2026 and December 9, 2026.
- Newer filing (2026-08-05) reports Rule 10b5-1 trading arrangement for Shan Riku Sakakibara entered June 8, 2026, covering sale of up to 12,000 shares and exercise of up to 8,000 stock options with sale of underlying shares between September 8, 2026 and December 9, 2026.
- Newer filing (2026-08-05) reports Rule 10b5-1 trading arrangement for Nancy Johnson entered June 9, 2026, covering sale of up to 25,582 shares and exercise of up to 30,000 stock options with sale of underlying shares between October 1, 2026 and December 31, 2026, to the extent not executed under her prior plan.
- Newer filing (2026-08-05) exhibit list includes Lease Agreement between BillionToOne, Inc. and TPI Investors 21, LLC dated April 19, 2024 (Exhibit 10.1).
- Newer filing (2026-08-05) exhibit list includes First Amendment to Lease Agreement dated August 29, 2025 (Exhibit 10.2).
- Newer filing (2026-08-05) exhibit list includes Lease Agreement between BillionToOne, Inc. and Whipple Road Portfolio, LLC dated June 23, 2026 (Exhibit 10.3).
- Removed:
- Older filing (2026-05-06) reported 'None' for unregistered sales of equity securities; newer filing replaces this with specific unregistered issuances.
- Older filing (2026-05-06) exhibit list included Amendment No. 2 to Development and Commercialization Agreement with Janssen Biotech, Inc., dated January 6, 2026 (Exhibit 10.1); not present in newer filing exhibit list.
- Older filing (2026-05-06) exhibit list included Annual Incentive Plan (Exhibit 10.2); not present in newer filing exhibit list.
- Older filing (2026-05-06) included Signatures page with dates May 6, 2026 and signatories Oguzhan Atay and Ross Taylor; newer filing excerpt does not include this signatures page.
- Reworded:
- Older filing (2026-05-06) heading: 'Item 2. Unregistered Sales Of Equity Securities And Use Of Proceeds' (capital 'Of' and 'And'); newer filing (2026-08-05) heading: 'Item 2. Unregistered Sales of Equity Securities and Use of Proceeds' (lowercase 'of' and 'and').
- Older filing (2026-05-06) disclosure period stated: 'During the fiscal quarter ended March 31, 2026'; newer filing (2026-08-05) states: 'During the fiscal quarter ended June 30, 2026'.
- Older filing (2026-05-06) trading arrangement dates were all March 6, 2026; newer filing (2026-08-05) reports arrangements dated June 2, 5, 8, and 9, 2026.
- Older filing (2026-05-06) David Tsao described as 'our President, Chief Technology Officer and Director'; newer filing (2026-08-05) describes him as 'our President, Chief Technology Officer and a member of our Board of Directors'.
- Older filing (2026-05-06) John ten Bosch plan period: June 15, 2026 to August 28, 2026; newer filing plan period: September 9, 2026 to December 4, 2026.
- Older filing (2026-05-06) Oguzhan Atay plan covered exercise of up to 120,000 stock options; newer filing covers up to 100,000 stock options.
- Older filing (2026-05-06) David Tsao plan covered exercise of up to 60,000 stock options; newer filing covers up to 70,000 stock options.
- Older filing (2026-05-06) Nancy Johnson plan covered sale of up to 29,000 shares between June 8, 2026 and August 31, 2026; newer filing covers up to 25,582 shares between October 1, 2026 and December 31, 2026, to the extent not executed under prior plan.
- Older filing (2026-05-06) Shan Riku Sakakibara plan covered sale of up to 20,000 shares between June 8, 2026 and August 31, 2026; newer filing covers up to 12,000 shares between September 8, 2026 and December 9, 2026.
- Notes:
- Newer filing excerpt is truncated mid-way through Exhibit 101.INS and lacks Signatures; older filing excerpt includes Signatures and more complete exhibit list descriptions.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 91 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 6 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 31 sells ($7M) — 3 selling insiders
- Last 90 days · read to 2026-10-160 buys · 91 sells ($30M) — 5 selling insiders
- Last 180 days · read to 2026-10-160 buys · 181 sells ($51M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-15. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BLLN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding BLLN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 332,516
- Reported value $39,895,270
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about BLLN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
BLLN had 2,818,267 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for BLLN because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 2,818,267
- Prior settlement (shares) 2,625,520
- Reported change 7.34%
- Days to cover (reported) 3.88
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Natera (NTRA)
- Guardant Health (GH)
- Exact Sciences (EXAS)
- Illumina (ILMN)
- Invitae (NVTA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BLLN vs…
BillionToOne, Inc. is found in…
BLLN ranks in…
Frequently asked questions
What does BillionToOne, Inc. (BLLN) do?
BillionToOne, Inc. is a molecular diagnostics company that develops and commercializes advanced diagnostic tests for the prenatal and oncology markets. The company leverages proprietary technology and artificial intelligence to improve the sensitivity and accuracy of its diagnostic platforms, aiming to expand its presence within large healthcare systems.
What sector is BillionToOne, Inc. (BLLN) in?
BillionToOne, Inc. (BLLN) is classified in the Health Care sector. Its industry is molecular diagnostics. It trades on NASDAQ.
Who are BillionToOne, Inc.'s (BLLN) competitors?
Notable peers of BillionToOne, Inc. (BLLN) include Natera, Guardant Health, Exact Sciences, Illumina and Invitae. This peer set is informational only — not financial advice.
Is BillionToOne, Inc. (BLLN) overbought or oversold right now?
BillionToOne, Inc. (BLLN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BLLN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.